Related Experiment Video
Updated: May 13, 2026

Glycomics-Guided Glycoproteomics Facilitates Comprehensive Profiling of the Glycoproteome in Complex Tumor Microenvironments
Published on: February 7, 2025
In-depth research of multidrug resistance related cell surface glycoproteome in gastric cancer
Kai Li1, Zhen Sun, Jianyong Zheng
1State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, the Fourth Military Medical University, 127 Changle Western Road, Xi'an, Shaanxi Province, 710032, China.
Abstract:
Human gastric cancer is a big public health problem. Multidrug resistance is a main obstacle to successful chemotherapeutic treatment in gastric cancers and the underlying mechanism is not clear. Glycosylation, one of the most important post translational modifications of proteins, plays a vital role in diverse aspects of tumor progression. In the present study, we applied two multidrug resistance cell lines and their parental drug sensitive gastric cancer cell line to a modified cell surface capturing strategy with triplex labeling to characterize MDR related cell surface glycoproteome. Finally, 56 cell membrane glycoproteins were successfully identified via combination of identification by glycopeptides and quantitation by non-glycopeptides, and 11 of them were found to be differentially expressed with the same trend in both drug resistant cell lines compared with that in sensitive cell line. The further analysis by western blot and in vitro drug sensitivity assay demonstrated that our approach is reliable and accurate and suggested that these glycoproteins may represent as biomarkers for multidrug resistance in gastric cancer.
Biological Significance:
In this study, we performed a cell surface glycoproteomics research of multidrug resistance in gastric cancer using a modified CSC approach. Totally we identified and quantified 11 membrane N-glycoproteins which were significantly changed in MDR gastric cancer cells. These glycoproteins are quite possible to be biomarkers for predicting MDR or key regulators for targeted therapy, and are also helpful for better interpreting the sophisticated mechanisms of MDR in gastric cancer. In addition to that, this approach used in this study can be well applied to screen aberrantly glycosylated biomarkers associated with other malignant phenotypes of various kinds of cancers.
Insights
Researchers identified 11 key cell surface glycoproteins associated with multidrug resistance in gastric cancer. These findings offer potential biomarkers for predicting resistance and guiding targeted therapies for this common disease.
Area of Science:
- Proteomics
- Glycobiology
- Oncology
Background:
- Gastric cancer poses a significant public health challenge globally.
- Multidrug resistance (MDR) hinders effective chemotherapy for gastric cancer patients.
- The mechanisms underlying MDR in gastric cancer remain incompletely understood.
Purpose of the Study:
- To characterize the cell surface glycoproteome associated with multidrug resistance in gastric cancer.
- To identify potential biomarkers for predicting MDR in gastric cancer.
- To explore novel therapeutic targets for overcoming MDR.
Main Methods:
- Utilized a modified cell surface capturing strategy with triplex labeling.
- Employed two multidrug-resistant gastric cancer cell lines and their drug-sensitive parental counterparts.
- Combined glycopeptide identification and non-glycopeptide quantitation for comprehensive analysis.
Main Results:
- Successfully identified 56 cell membrane glycoproteins.
- Quantified 11 differentially expressed membrane N-glycoproteins in MDR gastric cancer cells.
- Validated the reliability and accuracy of the approach through western blot and drug sensitivity assays.
Conclusions:
- Identified 11 N-glycoproteins as potential biomarkers for predicting MDR in gastric cancer.
- These glycoproteins may serve as key regulators for targeted therapy development.
- The study provides insights into the complex mechanisms of MDR in gastric cancer and offers a valuable approach for biomarker discovery in other cancers.

